Targeted inhibition of APOL1 channel function reduced proteinuria in patients with biopsy-proven FSGS and a high-risk APOL1 genotype in a small phase 2 study, providing evidence that toxic gain-of-function APOL1 variants contribute to proteinuric CKD.38 The gene discussed is APOL1; the disease is focal segmental glomerulosclerosis.